HomeCompareJWCTF vs XYLD

JWCTF vs XYLD: Dividend Comparison 2026

JWCTF yields 651.47% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWCTF wins by $503577.88M in total portfolio value
10 years
JWCTF
JWCTF
● Live price
651.47%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503577.90M
Annual income
$386,785,137,245.59
Full JWCTF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — JWCTF vs XYLD

📍 JWCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWCTFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWCTF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JWCTF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWCTF
Annual income on $10K today (after 15% tax)
$55,374.59/yr
After 10yr DRIP, annual income (after tax)
$328,767,366,658.75/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, JWCTF beats the other by $328,767,363,922.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWCTF + XYLD for your $10,000?

JWCTF: 50%XYLD: 50%
100% XYLD50/50100% JWCTF
Portfolio after 10yr
$251788.96M
Annual income
$193,392,570,232.30/yr
Blended yield
76.81%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWCTF buys
0
XYLD buys
0
No recent congressional trades found for JWCTF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWCTFXYLD
Forward yield651.47%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$503577.90M$25.3K
Annual income after 10y$386,785,137,245.59$3,219.02
Total dividends collected$493990.56M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: JWCTF vs XYLD ($10,000, DRIP)

YearJWCTF PortfolioJWCTF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$75,847$65,146.58$10,818$1,098.39+$65.0KJWCTF
2$542,945$461,789.28$11,738$1,222.51+$531.2KJWCTF
3$3,670,393$3,089,441.65$12,774$1,364.64+$3.66MJWCTF
4$23,446,108$19,518,787.95$13,944$1,527.86+$23.43MJWCTF
5$141,614,527$116,527,191.03$15,270$1,715.87+$141.60MJWCTF
6$809,307,352$657,779,808.21$16,775$1,933.09+$809.29MJWCTF
7$4,379,155,354$3,513,196,486.95$18,490$2,184.87+$4379.14MJWCTF
8$22,451,936,399$17,766,240,170.59$20,450$2,477.63+$22451.92MJWCTF
9$109,152,115,265$85,128,543,318.27$22,697$2,819.19+$109152.09MJWCTF
10$503,577,900,579$386,785,137,245.59$25,280$3,219.02+$503577.88MJWCTF

JWCTF vs XYLD: Complete Analysis 2026

JWCTFStock

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Full JWCTF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this JWCTF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWCTF vs SCHDJWCTF vs JEPIJWCTF vs OJWCTF vs KOJWCTF vs MAINJWCTF vs QYLDJWCTF vs JEPQJWCTF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.